Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
1964 5
1968 2
1969 1
1971 3
1973 1
1974 1
1975 3
1976 2
1977 1
1978 5
1979 5
1980 7
1981 6
1982 4
1983 4
1984 9
1985 11
1986 8
1987 8
1988 12
1989 9
1990 8
1991 8
1992 8
1993 8
1994 15
1995 10
1996 10
1997 5
1998 13
1999 18
2000 11
2001 12
2002 13
2003 12
2004 23
2005 22
2006 11
2007 15
2008 10
2009 14
2010 17
2011 22
2012 37
2013 29
2014 32
2015 31
2016 33
2017 40
2018 43
2019 35
2020 40
2021 42
2022 47
2023 40
2024 16

Text availability

Article attribute

Article type

Publication date

Search Results

774 results

Results by year

Filters applied: . Clear all
Page 1
Atorvastatin for Anthracycline-Associated Cardiac Dysfunction: The STOP-CA Randomized Clinical Trial.
Neilan TG, Quinaglia T, Onoue T, Mahmood SS, Drobni ZD, Gilman HK, Smith A, Heemelaar JC, Brahmbhatt P, Ho JS, Sama S, Svoboda J, Neuberg DS, Abramson JS, Hochberg EP, Barnes JA, Armand P, Jacobsen ED, Jacobson CA, Kim AI, Soumerai JD, Han Y, Friedman RS, Lacasce AS, Ky B, Landsburg D, Nasta S, Kwong RY, Jerosch-Herold M, Redd RA, Hua L, Januzzi JL, Asnani A, Mousavi N, Scherrer-Crosbie M. Neilan TG, et al. Among authors: svoboda j. JAMA. 2023 Aug 8;330(6):528-536. doi: 10.1001/jama.2023.11887. JAMA. 2023. PMID: 37552303 Free PMC article. Clinical Trial.
Compared with placebo, atorvastatin also reduced the incidence of the secondary end point (13% vs 29%; P = .001). There were 13 adjudicated heart failure events (4%) over 24 months of follow-up. There was no difference in the rates of incident heart failure between study g …
Compared with placebo, atorvastatin also reduced the incidence of the secondary end point (13% vs 29%; P = .001). There were 13 adjud …
Trial of Prasinezumab in Early-Stage Parkinson's Disease.
Pagano G, Taylor KI, Anzures-Cabrera J, Marchesi M, Simuni T, Marek K, Postuma RB, Pavese N, Stocchi F, Azulay JP, Mollenhauer B, López-Manzanares L, Russell DS, Boyd JT, Nicholas AP, Luquin MR, Hauser RA, Gasser T, Poewe W, Ricci B, Boulay A, Vogt A, Boess FG, Dukart J, D'Urso G, Finch R, Zanigni S, Monnet A, Pross N, Hahn A, Svoboda H, Britschgi M, Lipsmeier F, Volkova-Volkmar E, Lindemann M, Dziadek S, Holiga Š, Rukina D, Kustermann T, Kerchner GA, Fontoura P, Umbricht D, Doody R, Nikolcheva T, Bonni A; PASADENA Investigators; Prasinezumab Study Group. Pagano G, et al. Among authors: svoboda h. N Engl J Med. 2022 Aug 4;387(5):421-432. doi: 10.1056/NEJMoa2202867. N Engl J Med. 2022. PMID: 35921451 Clinical Trial.
The baseline mean MDS-UPDRS scores were 32.0 in the placebo group, 31.5 in the 1500-mg group, and 30.8 in the 4500-mg group, and mean (SE) changes from baseline to 52 weeks were 9.41.2 in the placebo group, 7.41.2 in the 1500-mg group (difference vs. placebo, -2.0; 80% confidence …
The baseline mean MDS-UPDRS scores were 32.0 in the placebo group, 31.5 in the 1500-mg group, and 30.8 in the 4500-mg group, and mean (SE) c …
Final results of MRC CRASH, a randomised placebo-controlled trial of intravenous corticosteroid in adults with head injury-outcomes at 6 months.
Edwards P, Arango M, Balica L, Cottingham R, El-Sayed H, Farrell B, Fernandes J, Gogichaisvili T, Golden N, Hartzenberg B, Husain M, Ulloa MI, Jerbi Z, Khamis H, Komolafe E, Laloë V, Lomas G, Ludwig S, Mazairac G, Muñoz Sanchéz Mde L, Nasi L, Olldashi F, Plunkett P, Roberts I, Sandercock P, Shakur H, Soler C, Stocker R, Svoboda P, Trenkler S, Venkataramana NK, Wasserberg J, Yates D, Yutthakasemsunt S; CRASH trial collaborators. Edwards P, et al. Among authors: svoboda p. Lancet. 2005 Jun 4-10;365(9475):1957-9. doi: 10.1016/S0140-6736(05)66552-X. Lancet. 2005. PMID: 15936423 Clinical Trial.
The risk of death was higher in the corticosteroid group than in the placebo group (1248 [25.7%] vs 1075 [22.3%] deaths; relative risk 1.15, 95% CI 1.07-1.24; p=0.0001), as was the risk of death or severe disability (1828 [38.1%] vs 1728 [36.3%] dead or severely disabled; …
The risk of death was higher in the corticosteroid group than in the placebo group (1248 [25.7%] vs 1075 [22.3%] deaths; relative risk 1.15, …
Effect of intravenous corticosteroids on death within 14 days in 10008 adults with clinically significant head injury (MRC CRASH trial): randomised placebo-controlled trial.
Roberts I, Yates D, Sandercock P, Farrell B, Wasserberg J, Lomas G, Cottingham R, Svoboda P, Brayley N, Mazairac G, Laloë V, Muñoz-Sánchez A, Arango M, Hartzenberg B, Khamis H, Yutthakasemsunt S, Komolafe E, Olldashi F, Yadav Y, Murillo-Cabezas F, Shakur H, Edwards P; CRASH trial collaborators. Roberts I, et al. Among authors: svoboda p. Lancet. 2004 Oct 9-15;364(9442):1321-8. doi: 10.1016/S0140-6736(04)17188-2. Lancet. 2004. PMID: 15474134 Clinical Trial.
FINDINGS: Compared with placebo, the risk of death from all causes within 2 weeks was higher in the group allocated corticosteroids (1052 [21.1%] vs 893 [17.9%] deaths; relative risk 1.18 [95% CI 1.09-1.27]; p=0.0001). The relative increase in deaths due to corticosteroids …
FINDINGS: Compared with placebo, the risk of death from all causes within 2 weeks was higher in the group allocated corticosteroids (1052 [2 …
Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson's disease.
Pagano G, Taylor KI, Anzures Cabrera J, Simuni T, Marek K, Postuma RB, Pavese N, Stocchi F, Brockmann K, Svoboda H, Trundell D, Monnet A, Doody R, Fontoura P, Kerchner GA, Brundin P, Nikolcheva T, Bonni A; PASADENA Investigators; Prasinezumab Study Group. Pagano G, et al. Among authors: svoboda h. Nat Med. 2024 Apr;30(4):1096-1103. doi: 10.1038/s41591-024-02886-y. Epub 2024 Apr 15. Nat Med. 2024. PMID: 38622249 Free PMC article.
Lower limb joint angles and their variability during uphill walking.
Sarvestan J, Ataabadi PA, Yazdanbakhsh F, Abbasi S, Abbasi A, Svoboda Z. Sarvestan J, et al. Among authors: svoboda z. Gait Posture. 2021 Oct;90:434-440. doi: 10.1016/j.gaitpost.2021.09.195. Epub 2021 Sep 25. Gait Posture. 2021. PMID: 34597985

In the knee joint, the sagittal (p < .001, eta(p)(2)>.14), frontal (p < .05, eta(p)(2)>.14), and transverse (p < .05, eta(p)(2)>.14) angles were significantly different (p < 0.05). Similarly, in the hip joint,

In the knee joint, the sagittal (p < .001, eta(p)(2)>.14), frontal (p < .05, eta(p)(2)>.14), and tra

Balance abilities of junior ice hockey players.
Ondra L, Svoboda Z. Ondra L, et al. Among authors: svoboda z. J Sports Med Phys Fitness. 2021 Feb;61(2):183-187. doi: 10.23736/S0022-4707.20.11057-0. Epub 2020 Jul 28. J Sports Med Phys Fitness. 2021. PMID: 32734754
RESULTS: The higher-level players performed better in the unilateral static stance task in both the anterior-posterior direction and the medial-lateral direction (with a P value of P<0.001), and total velocity (P=0.001). The higher-level players also perfo …
RESULTS: The higher-level players performed better in the unilateral static stance task in both the anterior-posterior direction and the med …
Benefits of the Dermocosmetic Mineral 89 Probiotic Fractions Adjunct to Topical Retinoids for Anti-Aging Benefits.
Valpaços C, Leclerc-Mercier S, Lopes L, Svoboda D, Miranda D, Correia P, Junior J, Fernandes E, Francois-Newton V, Mandary MB, Gueniche A, Tan J, Kerob D. Valpaços C, et al. Among authors: svoboda d. Clin Cosmet Investig Dermatol. 2023 Feb 10;16:375-385. doi: 10.2147/CCID.S396952. eCollection 2023. Clin Cosmet Investig Dermatol. 2023. PMID: 36798538 Free PMC article.
Tightness, dryness, burning, itching and stinging were reduced when compared to D7 (p<0.05). Dermatology Life Quality Index (DLQI) and Skindex 16 showed improvement in quality of life (p<0.05). IL-1RA increased at D28 (p=0.003) and PGE2 decreased at D28 …
Tightness, dryness, burning, itching and stinging were reduced when compared to D7 (p<0.05). Dermatology Life Quality Index (DLQI) …
Meniscal and Articular Cartilage Predictors of Outcome After Revision ACL Reconstruction: A 6-Year Follow-up Cohort Study.
MARS Group; Wright RW, Huston LJ, Haas AK, Pennings JS, Allen CR, Cooper DE, DeBerardino TM, Dunn WR, Lantz BBA, Spindler KP, Stuart MJ, Albright JP, Amendola AN, Andrish JT, Annunziata CC, Arciero RA, Bach BR Jr, Baker CL 3rd, Bartolozzi AR, Baumgarten KM, Bechler JR, Berg JH, Bernas GA, Brockmeier SF, Brophy RH, Bush-Joseph CA, Butler JB 5th, Campbell JD, Carey JL, Carpenter JE, Cole BJ, Cooper JM, Cox CL, Creighton RA, Dahm DL, David TS, Flanigan DC, Frederick RW, Ganley TJ, Garofoli EA, Gatt CJ Jr, Gecha SR, Giffin JR, Hame SL, Hannafin JA, Harner CD, Harris NL Jr, Hechtman KS, Hershman EB, Hoellrich RG, Johnson DC, Johnson TS, Jones MH, Kaeding CC, Kamath GV, Klootwyk TE, Levy BA, Ma CB, Maiers GP 2nd, Marx RG, Matava MJ, Mathien GM, McAllister DR, McCarty EC, McCormack RG, Miller BS, Nissen CW, O'Neill DF, Owens BD, Parker RD, Purnell ML, Ramappa AJ, Rauh MA, Rettig AC, Sekiya JK, Shea KG, Sherman OH, Slauterbeck JR, Smith MV, Spang JT, Svoboda LSJ, Taft TN, Tenuta JJ, Tingstad EM, Vidal AF, Viskontas DG, White RA, Williams JS Jr, Wolcott ML, Wolf BR, York JJ. MARS Group, et al. Among authors: svoboda lsj. Am J Sports Med. 2023 Mar;51(3):605-614. doi: 10.1177/03635465231151389. Epub 2023 Feb 3. Am J Sports Med. 2023. PMID: 36734487 Free PMC article.
Six-year Marx activity levels were negatively affected by having either a repair/excision of the medial meniscus (odds ratio range, 1.45-1.72; P .04) or grade 3-4 patellar chondrosis (odds ratio, 1.72; P = .04). Meniscal pathology occurring before the index revision …
Six-year Marx activity levels were negatively affected by having either a repair/excision of the medial meniscus (odds ratio range, 1.45-1.7 …
Lifestyle Walking Intervention for Patients With Heart Failure With Reduced Ejection Fraction: The WATCHFUL Trial.
Vetrovsky T, Siranec M, Frybova T, Gant I, Svobodova I, Linhart A, Parenica J, Miklikova M, Sujakova L, Pospisil D, Pelouch R, Odrazkova D, Parizek P, Precek J, Hutyra M, Taborsky M, Vesely J, Griva M, Semerad M, Bunc V, Hrabcova K, Vojkuvkova A, Svoboda M, Belohlavek J; WATCHFUL Investigators. Vetrovsky T, et al. Among authors: svoboda m. Circulation. 2024 Jan 16;149(3):177-188. doi: 10.1161/CIRCULATIONAHA.123.067395. Epub 2023 Nov 13. Circulation. 2024. PMID: 37955615 Free PMC article. Clinical Trial.
At 6 months, no between-group differences were detected in the 6MWT (mean 7.4 meters [95% CI, -8.0 to 22.7]; P=0.345, n=186). The intervention group increased their average daily step count by 1420 (95% CI, 749 to 2091) and daily minutes of moderate to vigorous physical ac …
At 6 months, no between-group differences were detected in the 6MWT (mean 7.4 meters [95% CI, -8.0 to 22.7]; P=0.345, n=186). The int …
774 results